He J, Li N, Chen W Q, Wu N, Shen H B, Jiang Y, Li J, Wang F, Tian J H
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing 211166, China.
Zhonghua Zhong Liu Za Zhi. 2021 Mar 23;43(3):243-268. doi: 10.3760/cma.j.cn112152-20210119-00060.
In China, the malignant tumor with the highest incidence and motality is lung cancer (LC). As screening and early detection and treatment are effective in reducing LC mortality, formulating a guideline in line with China's national conditions for the screening and early detection and treatment of LC will greatly promote the homogeneity and accuracy of LC screening, and result in an improvement of the effectiveness of LC screening. Commissioned and directed by the Disease Prevention and Control Bureau of the National Health Commission of the People's Republic of China, the guidline was initiated by the National Cancer Center of China and formulated with joint effort by experts from different disciplines. Following the principles and methods in WHO Handbook for Guideline Development, the guidline integrates the latest development in LC screening and early diagnosis and treatment worldwide while fully considering China's national conditions and practical experience in LC screening. It provides detailed evidence-based recommendations for different aspects of LC screening, such as the targeted population, the technologies and the procedures, to regulate the practices of LC screening and early diagnosis and treatment and enhance the effectiveness of the prevention and control of LC in China.
在中国，发病率和死亡率最高的恶性肿瘤是肺癌。由于筛查以及早期发现和治疗在降低肺癌死亡率方面具有成效，制定符合中国国情的肺癌筛查及早期发现和治疗指南将极大地促进肺癌筛查的同质性和准确性，并提高肺癌筛查的有效性。该指南由中华人民共和国国家卫生健康委员会疾病预防控制局委托并指导，由中国国家癌症中心发起，不同学科的专家共同制定。该指南遵循世界卫生组织《指南制定手册》中的原则和方法，在充分考虑中国国情和肺癌筛查实践经验的同时，整合了全球肺癌筛查及早期诊断和治疗的最新进展。它针对肺癌筛查的不同方面，如目标人群、技术和程序等，提供了详细的循证建议，以规范肺癌筛查及早期诊断和治疗的实践，并提高中国肺癌防控的有效性。
